Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

• Unité de recherche: INNOSUISSE
• Numéro de projet: 60677.1 IP-LS
• Titre du projet anglais: Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

Description succincte (Allemand)

Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

Description succincte (Anglais)

Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis.

Résumé des résultats (Abstract) (Allemand)

Idiopathic pulmonary fibrosis (IPF) is a form of restrictive interstitial lung disease (ILD) associated with extremely poor outcomes. With our approach based on a unique mode of action drug that restores cGMP levels, we aim to stop lung fibrosis progression and increase the survival rate.